https://orcid.org/0000-0003-0496-5064
Overview
Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center. Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and complement-mediated diseases. Dr. Arepally’s long-standing research program investigates the immune pathogenesis of heparin induced thrombocytopenia (HIT). Current laboratory efforts focus on the role of complement activation in antibody production and thrombosis in HIT, studies of complement inhibitors for immune-complex mediated diseases and diagnostic biomarkers of platelet activation.
Current Appointments & Affiliations
Professor of Medicine
·
2018 - Present
Medicine, Hematology,
Medicine
Associate Professor of Pathology
·
2009 - Present
Pathology,
Clinical Science Departments
Professor of Pathology
·
2018 - Present
Pathology,
Clinical Science Departments
Recent Publications
Red cell exchange removes apixaban in patients with sickle cell disease.
Journal Article Transfusion · May 7, 2026 BACKGROUND: Many patients with sickle cell disease undergo red cell exchange (RCE) and are anticoagulated with apixaban for treatment and/or prevention of venous thromboembolism. Prior studies have demonstrated that apixaban can bind to red blood cells (RB ... Full text Link to item CiteThe influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.
Journal Article J Immunol · April 15, 2026 Systemic lupus erythematosus (SLE) is a systemic autoimmune disease in which immune complexes (ICs) consisting of antinuclear autoantibodies (ANAs) and nuclear antigens induce complement activation and contribute to disease pathogenesis. The impact of anti ... Full text Link to item CiteHeparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner.
Journal Article J Thromb Haemost · March 4, 2026 BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction to heparin caused by pathological immunoglobulin G (IgG) antibodies targeting platelet factor (PF) 4/heparin antigenic complexes. Immune complexes (ICs) consisting of IgG antibo ... Full text Link to item CiteRecent Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030The role of cerebrospinal fluid complement activation in delirium and post-intensive care unit long-term cognitive impairment
ResearchAdvisor · Awarded by National Institute on Aging · 2024 - 2029Complement and thrombosis in HIT
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2028View All Grants
Education
Vanderbilt University ·
1989
M.D.